Full Press Release Details
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting.
ALXO
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
Key Takeaway: ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
Price reaction · baseline $61.93 (2021-11-03 close) · hit after-hours · 1 other ALXO headline(s) in the window, move may be shared
day 0 close
-15.5%
day 1
-17.7%
day 3 · peak
-33.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)